<DOC>
	<DOCNO>NCT01729403</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled study evaluate effect aleglitazar insulin sensitivity patient type 2 diabetes mellitus inadequately control metformin monotherapy . Patients randomize receive either aleglitazar 150 mcg placebo orally daily 16 week , addition exist dose regimen metformin .</brief_summary>
	<brief_title>A Study The Effect Aleglitazar Insulin Sensitivity Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Adult patient , 30 70 year age inclusive screening Type 2 diabetes mellitus patient treat stable metformin therapy least 12 week prior screen ; metformin dose exceed maximum dose specify label HbA1c &gt; /= 6.5 % &lt; /= 9 % screen baseline Fasting plasma glucose &lt; /= 13.3 mmol/L ( &lt; /= 240 mg/dl ) screen baseline Body mass index ( BMI ) &gt; /= 25 screening ; BMI &gt; /= 27 subject HbA1c &lt; 7 % Stable weight +/ 5 % least 12 week prior screen Women pregnant , intend become pregnant study period , currently lactate woman , woman childbearing potential use highly effective , medically approve birth control method Diagnosis history type 1 diabetes mellitus , diabetes result pancreatic injury , secondary form diabetes Acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month Any previous treatment thiazolidinedione dual peroxisome proliferator activate receptor ( PPAR ) agonist Any body weight lower lipoproteinmodifying therapy ( e.g . fibrates ) within 12 week prior screen exception stable ( &gt; /= 1 month ) statin therapy History bariatric surgery currently undergo evaluation bariatric surgery Prior intolerance fibrate Treatment antidiabetic medication metformin last 12 week prior screen and/or herbal/overthecounter preparation may affect glycemic control within 12 week prior screen Clinically apparent liver disease Positive hepatitis B , hepatitis C HIV infection Clinical evidence anemia Symptomatic congestive heart failure ( New York Heart Association Class IIIV ) screen Myocardial infarction , acute coronary syndrome , transient ischemic attack/stroke within 6 month prior screen Known macular edema screen prior screen visit Uncontrolled hypertension despite stable ( least 4 week ) antihypertensive treatment Diagnosed and/or treat malignancy ( except treat case basal cell skin cancer , situ carcinoma cervix situ prostate cancer ) within past 5 year Chronic oral parenteral corticosteroid treatment ( &gt; 2 week ) within 3 month prior screen History active substance abuse ( include alcohol ) within past 2 year positive test result drug abuse alcohol prior first dose Presence absolute relative contraindication conduct magnetic resonance imaging ( MRI ) investigation</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>